Company Overview
iTonic Holdings Ltd., a healthcare solutions provider, develops and commercializes treatment software and devices used for brachytherapy. The company's proprietary treatment planning system is a radioactive particle implantation, a radiotherapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. The company offers FTTPS, a treatment planning system for treating various malignant tumors, which could determine the target volume, prescription dose, and dose limitation to protect organs at risks and produce a safe, effective, and accurate dose distribution plan for brachytherapy for cancer patients. The company was formerly known as Pheton Holdings Ltd and changed its name to iTonic Holdings Ltd. in January 2026. iTonic Holdings Ltd. was founded in 1998 and is headquartered in Beijing, China. iTonic Holdings Ltd. operates as a subsidiary of ZJW (BVI) LTD.
Recent Developments
- Dec 2025 Revenue of $523.03K (+16.7% YoY); net profit $-5.10M.
- Trailing 12 Months Year-on-year growth — revenue +91.6%.
- 5-Year Trend Long-term compounding — revenue CAGR -8.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -8.37% |
| 1 Year: | 91.60% |
Stock Price Performance
| 1 Year: | -52.83% |
| 6 Months: | -14.83% |
| 3 Months: | -39.41% |
| 1 Month: | +6.46% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)52.72 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -8.4% CAGR over 5 years.
- Trading 70.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ITOC iTonic Holdings Ltd. PHARMA | 0.31 | -0.97 | $2.91M | 0.00% | -59.82% | -71.25% | -8.37% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 679.78K | 628.59K | 448.20K | 523.03K |
| Cost of Revenue | - | 121.63K | 157.76K | 67.04K | 195.68K |
| Gross Profit | - | 558.15K | 470.83K | 381.15K | 327.35K |
| Operating Expenses | - | 483.62K | 729.34K | 1.04M | 5.49M |
| Operating Income | - | 74.53K | -258.51K | -661.96K | -5.16M |
| EBITDA | - | 128.61K | -195.38K | -589.53K | -5.15M |
| Interest Expense | - | - | - | - | - |
| Pretax Income | - | 71.03K | -260.51K | -638.76K | -5.10M |
| Tax Provision | - | -12.95K | -19.29K | 21.83K | 0 |
| Net Income | - | 83.98K | -241.22K | -660.59K | -5.10M |
| Diluted EPS | 0.03 | 0.01 | -0.02 | -0.05 | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 1.40M | 1.62M | 6.72M | 9.10M |
| Current Assets | - | 718.80K | 532.47K | 6.68M | 4.09M |
| Cash & Equivalents | - | 72.29K | 217.88K | 6.16M | 1.49M |
| Inventory | - | 152.79K | 52.26K | 117.42K | 52.48K |
| Receivables | - | 448.07K | 206.33K | 281.58K | 288.46K |
| Total Liabilities | - | 845.41K | 1.31M | 538.55K | 969.83K |
| Current Liabilities | - | 680.40K | 1.21M | 538.55K | 462.82K |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 218.33K | 155.82K | 247.97K | 143.00K |
| Total Equity | - | 556.32K | 306.27K | 6.18M | 6.12M |
| Shares Outstanding | - | 14.25M | 14.25M | 14.25M | 17.05M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -116.15K | -63.64K | -775.00K | -3.23M |
| Investing Cash Flow | - | 0 | 0 | -861 | -1.35M |
| Financing Cash Flow | - | 78.14K | 220.59K | 6.71M | -91.64K |
| Capital Expenditure | - | - | - | -861 | -3.81K |
| Free Cash Flow | - | -116.15K | -63.64K | -775.86K | -3.24M |
| Net Change in Cash | - | -38.02K | 156.96K | 5.94M | -4.68M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 82.1% | 74.9% | 85.0% | 62.6% |
| Operating Margin % | - | 11.0% | -41.1% | -147.7% | -987.5% |
| Net Margin % | - | 12.4% | -38.4% | -147.4% | -974.7% |
| ROE % | - | 15.1% | -78.8% | -10.7% | -83.3% |
| ROCE % | - | 10.3% | -62.9% | -10.7% | -59.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Xtx Topco Ltd | 0.81% | 75.89K | $24.25K |
| 2 | Renaissance Technologies, LLC | 0.47% | 44.08K | $14.09K |
| 3 | Citadel Advisors Llc | 0.46% | 43.38K | $13.86K |
| 4 | Virtu Financial LLC | 0.41% | 38.61K | $12.34K |
| 5 | UBS Group AG | 0.35% | 33.29K | $10.64K |
| 6 | Jane Street Group, LLC | 0.19% | 17.84K | $5.70K |
| 7 | Stonex Group Inc. | 0.12% | 11.04K | $3.53K |
| 8 | Point72 Asset Management, L.P. | 0.12% | 10.85K | $3.47K |
| 9 | National Bank of Canada/FI/ | 0.02% | 1.80K | $575 |
| 10 | Blackrock Inc. | 0.01% | 618 | $197 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ITOC
iTonic Holdings Ltd Issues an Update on its Effort to Develop AI-Powered Cloud Healthcare Platform Designed to Support Nuclear Medicine Treatment Planning and with Potential Future Expansion into Digital Care Delivery
New cloud-based platform is being developed to integrate artificial intelligence, automated quality control and healthcare data connectivity to support next-generation precision medicine workflows. Beijing, China, July 15, 2026 (GLOBE NEWSW…
iTonic Holdings Ltd Granted An Extension of Additional 180-Day by Nasdaq to Regain Compliance with Minimum Bid Price Rule
BEIJING, China, April 23, 2026 (GLOBE NEWSWIRE) -- iTonic Holdings Ltd (the “Company” or “ITOC”), a healthcare solution provider specializing in treatment planning systems for brachytherapy and other related products and services, today ann…
ITOC — Frequently Asked Questions
What is the current share price of iTonic Holdings Ltd. (ITOC)?
As of 2026-09-19 21:16 PDT, iTonic Holdings Ltd. (ITOC) trades at $0.31 on NasdaqCM. Its 52-week range is $0.25 to $1.03.
What is the market capitalisation of ITOC?
iTonic Holdings Ltd. (ITOC) has a market capitalisation of $2.91M on NasdaqCM.
What is the P/E ratio of ITOC?
ITOC trades at a trailing price-to-earnings (P/E) ratio of -0.97. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.89.
What is the return on equity (ROE) of ITOC?
ITOC has a return on equity (ROE) of -71.25%. Its return on capital employed (ROCE) is -59.82%.
Is ITOC a good stock to buy?
This page provides a data-driven analysis of iTonic Holdings Ltd. (ITOC), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.